Recently, the drug Keytruda has been found to help effectively stop tumor growth in mesothelioma patients. In the clinical trial, American pharmaceutical company, Merck, saw a 76% disease control rate. Users have testified to its success, claiming it is a “life saver.”
While the treatment is promising, it is also expensive for those who wish to use it. There is currently a petition circulating campaigning to have the drug fast-tracked on the Pharmaceutical Benefits Scheme (PBS). Fast-tracking this process will ensure that more patients have greater access to the drug sooner than later.
It is estimated that 3,000 individuals are diagnosed with mesothelioma each year in the United States. This rare cancer, which is known to be caused by asbestos exposure, has no cure, making treatment options slim. Patients often opt to participate in clinical trials such as Merck’s Keytruda trial.
With such positive results from the clinical trial, many patients and their families believe that this is the mesothelioma treatment they have been waiting for. Have you or a family member had a positive experience with Keytruda as a mesothelioma treatment option? Please share your story with us in a comment below.